Literature DB >> 25193880

Effects of iron depletion on CALM-AF10 leukemias.

Catherine P Lavau1, Daniel S Wechsler1,2, Jessica L Heath1, Joshua M Weiss1.   

Abstract

Iron, an essential nutrient for cellular growth and proliferation, enters cells via clathrin-mediated endocytosis. The clathrin assembly lymphoid myeloid (CALM) protein plays an essential role in the cellular import of iron by clathrin-mediated endocytosis. CALM-AF10 leukemias harbor a single copy of the normal CALM gene and therefore may be more sensitive to the growth-inhibitory effect of iron restriction compared with normal hematopoietic cells. We found that CALM heterozygous (CALM(HET)) murine fibroblasts exhibit signs of iron deficiency, with increased surface transferrin receptor levels and reduced growth rates. CALM(HET) hematopoietic cells are more sensitive in vitro to iron chelators than their wild type counterparts. Iron chelation also displayed toxicity toward cultured CALM(HET)CALM-AF10 leukemia cells, and this effect was additive to that of chemotherapy. In mice transplanted with CALM(HET)CALM-AF10 leukemia, we found that dietary iron restriction reduced tumor burden in the spleen. However, dietary iron restriction, used alone or in conjunction with chemotherapy, did not increase survival of mice with CALM(HET)CALM-AF10 leukemia. In summary, although CALM heterozygosity results in iron deficiency and increased sensitivity to iron chelation in vitro, our data in mice do not suggest that iron depletion strategies would be beneficial for the therapy of CALM-AF10 leukemia patients.
Copyright © 2014 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25193880      PMCID: PMC4261044          DOI: 10.1016/j.exphem.2014.08.004

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  36 in total

1.  Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia.

Authors:  Toshihiro Fukushima; Hiroshi Kawabata; Takuji Nakamura; Haruka Iwao; Akio Nakajima; Miyuki Miki; Tomoyuki Sakai; Toshioki Sawaki; Yoshimasa Fujita; Masao Tanaka; Yasufumi Masaki; Yuko Hirose; Hisanori Umehara
Journal:  Anticancer Res       Date:  2011-05       Impact factor: 2.480

2.  Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone.

Authors:  R C DeConti; B R Toftness; K C Agrawal; R Tomchick; J A Mead; J R Bertino; A C Sartorelli; W A Creasey
Journal:  Cancer Res       Date:  1972-07       Impact factor: 12.701

3.  Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas.

Authors:  H L Elford; M Freese; E Passamani; H P Morris
Journal:  J Biol Chem       Date:  1970-10-25       Impact factor: 5.157

4.  Kinetics of transit of transferrin and epidermal growth factor through clathrin-coated membranes.

Authors:  J A Hanover; M C Willingham; I Pastan
Journal:  Cell       Date:  1984-12       Impact factor: 41.582

5.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

6.  The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.

Authors:  V Ashutosh Rao; Sarah R Klein; Keli K Agama; Eriko Toyoda; Noritaka Adachi; Yves Pommier; Emily B Shacter
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

7.  Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells.

Authors:  Egarit Noulsri; Des R Richardson; Surada Lerdwana; Suthat Fucharoen; Tetsuo Yamagishi; Danuta S Kalinowski; Kovit Pattanapanyasat
Journal:  Am J Hematol       Date:  2009-03       Impact factor: 10.047

8.  MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis.

Authors:  M H Dreyling; K Schrader; C Fonatsch; B Schlegelberger; D Haase; C Schoch; W Ludwig; H Löffler; T Büchner; B Wörmann; W Hiddemann; S K Bohlander
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

9.  The clathrin assembly protein PICALM is required for erythroid maturation and transferrin internalization in mice.

Authors:  Mai Suzuki; Hirokazu Tanaka; Akira Tanimura; Kenji Tanabe; Natsuko Oe; Shinya Rai; Syunsuke Kon; Manabu Fukumoto; Kohji Takei; Takaya Abe; Itaru Matsumura; Yuzuru Kanakura; Toshio Watanabe
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

Review 10.  Iron deprivation in cancer--potential therapeutic implications.

Authors:  Jessica L Heath; Joshua M Weiss; Catherine P Lavau; Daniel S Wechsler
Journal:  Nutrients       Date:  2013-07-24       Impact factor: 5.717

View more
  5 in total

1.  In Vitro Antileukemic Activity of Xanthosoma sagittifolium (Taioba) Leaf Extract.

Authors:  Marina L C Caxito; Rachell R Correia; Anne Caroline C Gomes; Graça Justo; Marsen G P Coelho; Cássia M Sakuragui; Ricardo M Kuster; Katia C C Sabino
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-09       Impact factor: 2.629

2.  CXCR4 Mediates Enhanced Cell Migration in CALM-AF10 Leukemia.

Authors:  Shelby A Fertal; Sayyed K Zaidi; Janet L Stein; Gary S Stein; Jessica L Heath
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

3.  A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML.

Authors:  Bo-Rui Chen; Anagha Deshpande; Karina Barbosa; Maria Kleppe; Xue Lei; Narayana Yeddula; Pablo Sánchez Vela; Alexandre Rosa Campos; Robert J Wechsler-Reya; Anindya Bagchi; Soheil Meshinchi; Connie Eaves; Irmela Jeremias; Torsten Haferlach; David A Frank; Ze'ev Ronai; Sumit Chanda; Scott A Armstrong; Peter D Adams; Ross L Levine; Aniruddha J Deshpande
Journal:  Blood       Date:  2021-06-17       Impact factor: 25.476

4.  Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.

Authors:  Claire Legendre; Sylvie Avril; Catherine Guillet; Emmanuel Garcion
Journal:  BMC Cancer       Date:  2016-02-01       Impact factor: 4.430

Review 5.  Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

Authors:  Hui Yu; Yuxin Du; Ji Xu; Mingzhi Zhang
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.